Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis



      Polmacoxib, a new coxib dually inhibiting cyclooxygenase-2 and carbonic anhydrase I/II, was recently approved for osteoarthritis treatment in South Korea. This study explored the population pharmacokinetic and pharmacodynamic characteristics of polmacoxib.


      Nonlinear mixed-effects modeling was performed using pooled pharmacokinetic data from a Phase I study in healthy individuals and pharmacokinetic properties and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) data from a Phase IIb study in patients with osteoarthritis. Pharmacodynamic models for WOMAC were sequentially fit using individual pharmacokinetic parameter estimates.


      Polmacoxib concentrations in whole blood were adequately described by the 2-compartment model, with mixed zero- and first-order absorption kinetics. Iron concentration was the significant covariate associated with clearance of polmacoxib. The relationship between the whole blood concentration of polmacoxib and WOMAC was best described by a 2-effect compartment model that consisted of central and peripheral compartments with the rate constant of 0.408 min−1 for distribution to the central effect compartment. A decrease in WOMAC was linked to the central effect site compartment concentration through an ordinary maximum effect model with an effect site concentration needed to achieve 50% of the maximum effect of 508 ng/mL.


      The current model accurately characterized the pharmacokinetic and pharmacodynamic properties of polmacoxib and could provide a basis for individualized drug therapy.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Brooks P.M.
        The burden of musculoskeletal disease–a global perspective.
        Clinical rheumatology. 2006; 25: 778-781
        • Pereira D.
        • Peleteiro B.
        • Araujo J.
        • Branco J.
        • Santos R.A.
        • Ramos E.
        The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review.
        Osteoarthritis and cartilage. 2011; 19: 1270-1285
        • Buckwalter J.A.
        • Saltzman C.
        • Brown T.
        The impact of osteoarthritis: implications for research.
        Clinical orthopaedics and related research. 2004; 427: S6-15
        • Gupta S.
        • Hawker G.A.
        • Laporte A.
        • Croxford R.
        • Coyte P.C.
        The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition.
        Rheumatology (Oxford, England). 2005; 44: 1531-1537
        • Sinusas K.
        Osteoarthritis: diagnosis and treatment.
        American family physician. 2012; 85: 49-56
        • Hinton R.
        • Moody R.L.
        • Davis A.W.
        • Thomas S.F.
        Osteoarthritis: diagnosis and therapeutic considerations.
        American family physician. 2002; 65: 841-848
        • Hochberg M.C.
        • Altman R.D.
        • April K.T.
        • Benkhalti M.
        • Guyatt G.
        • McGowan J.
        • et al.
        American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee.
        Arthritis care & research. 2012; 64: 465-474
        • Scott D.L.
        • Shipley M.
        • Dawson A.
        • Edwards S.
        • Symmons D.P.
        • Woolf A.D.
        The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness.
        British journal of rheumatology. 1998; 37: 546-554
        • Heerdink E.R.
        • Leufkens H.G.
        • Herings R.M.
        • Ottervanger J.P.
        • Stricker B.H.
        • Bakker A.
        NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.
        Archives of internal medicine. 1998; 158: 1108-1112
        • Hunt R.H.
        • Choquette D.
        • Craig B.N.
        • De Angelis C.
        • Habal F.
        • Fulthorpe G.
        • et al.
        Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?.
        Canadian family physician Medecin de famille canadien. 2007; 53: 1177-1184
        • Laporte J.R.
        • Carne X.
        • Vidal X.
        • Moreno V.
        • Juan J.
        Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding.
        Lancet (London, England). 1991; 337: 85-89
        • Grosser T.
        The pharmacology of selective inhibition of COX-2.
        Thrombosis and haemostasis. 2006; 96: 393-400
        • Silverstein F.E.
        • Faich G.
        • Goldstein J.L.
        • Simon L.S.
        • Pincus T.
        • Whelton A.
        • et al.
        Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
        JAMA. 2000; 284124755
        • Krotz F.
        • Schiele T.M.
        • Klauss V.
        • Sohn H.Y.
        Selective COX-2 inhibitors and risk of myocardial infarction.
        Journal of vascular research. 2005; 42: 312-324
        • Flavahan N.A.
        Balancing prostanoid activity in the human vascular system.
        Trends in pharmacological sciences. 2007; 28: 106-110
        • Ruan C.H.
        • So S.P.
        • Ruan K.H.
        Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease.
        Life sciences. 2011; 88: 24-30
        • Aljadhey H.
        • Tu W.
        • Hansen R.A.
        • Blalock S.J.
        • Brater D.C.
        • Murray M.D.
        Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension.
        BMC cardiovascular disorders. 2012; 12: 93
        • Aw T.J.
        • Haas S.J.
        • Liew D.
        • Krum H.
        Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.
        Archives of internal medicine. 2005; 165: 490-496
        • Skarke C.
        • Alamuddin N.
        • Lawson J.A.
        • Cen L.
        • Propert K.J.
        • Fitzgerald G.A.
        Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.
        Clinical pharmacology and therapeutics. 2012; 91: 986-993
        • Hirankarn S.
        • Barrett J.S.
        • Alamuddin N.
        • FitzGerald G.A.
        • Skarke C.
        GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies.
        Clinical pharmacology in drug development. 2013; 2: 379-386
        • Kim M.J.
        • Lim H.S.
        • Jin S.
        • Jung J.A.
        • Noh Y.H.
        • Kim Y.H.
        • et al.
        Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women.
        Clinical therapeutics. 2015; 37: 197-210
        • Kim H.T.
        • Cha H.
        • Hwang K.Y.
        Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649).
        Biochemical and biophysical research communications. 2016; 478: 1-6
        • Lionetto M.G.
        • Caricato R.
        • Giordano M.E.
        • Erroi E.
        • Schettino T.
        Carbonic anhydrase and heavy metals.
        Biochemistry. InTech, London, UK2012
        • Ashraf A.
        • Siddiqui W.A.
        • Akbar J.
        • Mustafa G.
        • Krautscheid H.
        • Ullah N.
        • et al.
        Metal complexes of benzimidazole derived sulfonamide: Synthesis, molecular structures and antimicrobial activity.
        Inorganica Chimica Acta. 2016; 443: 179-185
        • Rocca B.
        • FitzGerald G.A.
        Cyclooxygenases and prostaglandins: shaping up the immune response.
        International immunopharmacology. 2002; 2: 603-630
        • Renton K.W.
        Alteration of drug biotransformation and elimination during infection and inflammation.
        Pharmacology & therapeutics. 2001; 92: 147-163
        • Renton K.W.
        Regulation of drug metabolism and disposition during inflammation and infection.
        Expert opinion on drug metabolism & toxicology. 2005; 1: 629-640
        • Mangoni A.A.
        • Jackson S.H.
        Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.
        British journal of clinical pharmacology. 2004; 57: 6-14
        • Shi S.
        • Klotz U.
        Age-related changes in pharmacokinetics.
        Current drug metabolism. 2011; 12: 601-610
        • Youn Choi H.
        • Jin S.J.
        • Jung J.A.
        • Kim U.J.
        • Ko Y.J.
        • Noh Y.H.
        • et al.
        Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers.
        Clinical therapeutics. 2014; 36: 115-125
        • Fan H.W.
        • Liu G.Y.
        • Zhao C.F.
        • Li X.F.
        • Yang X.Y.
        Differential expression of COX-2 in osteoarthritis and rheumatoid arthritis.
        Genetics and molecular research. 2015; 14: 12872-12879
        • Iniguez M.A.
        • Pablos J.L.
        • Carreira P.E.
        • Cabre F.
        • Gomez-Reino J.J.
        Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases.
        British journal of rheumatology. 1998; 37: 773-778
        • Zweers M.C.
        • de Boer T.N.
        • van Roon J.
        • Bijlsma J.W.
        • Lafeber F.P.
        • Mastbergen S.C.
        Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis.
        Arthritis research & therapy. 2011; 13: 239